title: Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells.
abstract: Cladribine (2-CDA) is a well-known purine nucleoside analog with activities against lymphoproliferative disorders such as hairy cell leukemia (HCL). Bendamustine, a hybrid molecule of purine analog and alkylator, induces apoptosis via DNA damage response and inhibition of mitotic checkpoint. Their therapeutic potential in patients with multiple myeloma (MM), particularly those become resistant to traditional chemotherapeutic agents, remains unclear. Here we study the effects of cladribine or bendamustine on dexamethasone-sensitive (MM1.S) and -resistant (MM1.R) MM cells. MTS-based proliferation assays showed that cladribine and bendamustine exhibited similar anti-proliferation/anti-survival effects on MM1.S and MM1.R cells in a dose-dependent manner. The IC50s of cladribine were approximately 35.3 nmol/L and 58 nmol/L for MM1.S and MM1.R cells, respectively. The IC50s of bendamustine were approximately 119.8 μmol/L (MM1.S) and 138 μmol/L (MM1.R). An apoptotic-ELISA and western blot assays of PARP cleavage and activation of caspase-8 and caspase-3 indicated that cladribine or bendamustine induced apoptosis in both cell lines. Similar results were obtained with flow cytometric analysis showing that cladribine or bendamustine increased the sub-G1 population. Treatment with bendamustine but not cladribine also resulted in cell cycle S-phase arrest. Either cladribine or bendamustine led to a remarkable increase of the phosphorylated H2A.X, CHK1 and CHK2 in both MM1.S and MM1.R cells, suggesting an induction of DNA damage response. Collectively, we demonstrate that cladribine and bendamustine exert potent inhibitory effects on dexamethasone-sensitive and -resistant MM cells in vitro. Our data suggest that MM patients, including those with dexamethasone resistance, may particularly benefit from cladribine or bendamustine.
authors: Department of Hematology, Chinese PLA General Hospital Beijing, China ; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus Aurora, CO, USA.
authors: Bo
authors: B
authors: Cai
authors: Shuiliang
authors: S
authors: Wang
authors: Jingcao
authors: J
authors: Huang
authors: Choon-Kee
authors: CK
authors: Lee
authors: Chunji
authors: C
authors: Gao
authors: Bolin
authors: B
authors: Liu
keywords: Cladribine; DNA damage response; apoptosis; bendamustine; dexamethasone resistance; multiple myeloma
references: J Clin Oncol. 2012 Jul 10;30(20):2441-8
references: 22508825
references: Int J Oncol. 2009 May;34(5):1329-40
references: 19360345
references: Haematologica. 2001 May;86(5):485-93
references: 11410411
references: Ann Hematol. 1994 Nov;69(5):223-30
references: 7948311
references: Immunity. 1999 Jan;10(1):105-15
references: 10023775
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Clin Cancer Res. 2007 Jul 1;13(13):3771-5
references: 17606706
references: Blood. 2010 Oct 21;116(16):2884-96
references: 20634380
references: J Clin Invest. 1985 Feb;75(2):377-83
references: 2579098
references: Curr Cancer Drug Targets. 2005 Sep;5(6):421-44
references: 16178817
references: Expert Opin Pharmacother. 2012 Jul;13(10):1495-505
references: 22663160
references: Cancer. 2009 Jan 1;115(1):94-100
references: 19025975
references: Blood. 2012 May 17;119(20):4608-13
references: 22451423
references: Leuk Lymphoma. 2010 Aug;51(8):1485-93
references: 20578816
references: Oncogene. 2001 Sep 20;20(42):5991-6000
references: 11593406
references: Br J Haematol. 2011 Dec;155(5):632-4
references: 21689088
references: Clin Cancer Res. 2008 Jan 1;14(1):309-17
references: 18172283
references: Leuk Res. 1996 Feb;20(2):155-60
references: 8628014
references: Curr Opin Oncol. 2004 Nov;16(6):553-63
references: 15627017
references: Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):123-36
references: 18537755
references: Blood. 1992 Sep 15;80(6):1626
references: 1355673
references: Cancer. 2009 Feb 1;115(3):473-9
references: 19117340
references: Future Oncol. 2010 Mar;6(3):407-18
references: 20222797
references: J Clin Oncol. 2003 Mar 1;21(5):891-6
references: 12610190
references: Leukemia. 2011 Dec;25(12):1891-9
references: 21788946
references: Anticancer Drugs. 2007 Jun;18(5):587-95
references: 17414628
references: BMC Cancer. 2011 Jun 16;11:255
references: 21679466
references: Blood. 1993 Feb 1;81(3):868-9
references: 7679003
references: Clin Pharmacokinet. 1997 Feb;32(2):120-31
references: 9068927
references: Leuk Lymphoma. 2012 Apr;53(4):632-4
references: 21916831
references: Oncogene. 1997 Aug 14;15(7):837-43
references: 9266970
references: Exp Hematol. 2003 Apr;31(4):271-82
references: 12691914
references: Br J Cancer. 1993 Jan;67(1):10-4
references: 8094002
references: Cancer Lett. 2010 Oct 28;296(2):233-40
references: 20447761
references: J Clin Oncol. 2010 Apr 10;28(11):1863-9
references: 20212251